This paper seeks to answer a key question: Does controlling the availability of certain chemicals (precursors) affect drug markets? Essentially, it wants to find out if restricting access to substances used in making illegal drugs can reduce drug use, trafficking, and related issues like overdoses. To explore this, the paper will critically analyse existing research, which primarily focuses on American literature, particularly the works led by James K. Cunningham and his team. The research shows that the regulation of chemicals essential to produce drugs such as heroin, cocaine, and methamphetamine is associated with several positive outcomes. These include a decrease in drug purity, a reduction in seizures, lower demand for treatment and hospitalization, and an increase in drug prices. This decrease in harmful outcomes results from a combination of diminished overall consumption and a reduction in harm per dose. However, the paper also highlights significant gaps in the current literature that need addressing to fully understand the impact of precursor regulation. These include questions about the external validity of these studies, the extent of regulation implementation and enforcement, and potential economic side effects, given that some of these chemicals also have legitimate uses in the chemical and pharmaceutical industries. Despite certain limitations in the evidence base, regulating precursors emerges as a promising strategy to diminish drug availability and its associated issues. This approach could be a cost-effective way to tackle the growing problem of synthetic opioids like fentanyl, which are already widespread in North America and are becoming more prevalent in Europe. In 2021, the United States saw an average of 220 deaths per day from opioid overdoses. Regulating drugs precursors could help save some of these lives.